title: Leucine and HMB differentially modulate proteasome system in skeletal muscle under different sarcopenic conditions.
abstract: In the present study we have compared the effects of leucine supplementation and its metabolite β-hydroxy-β-methyl butyrate (HMB) on the ubiquitin-proteasome system and the PI3K/Akt pathway during two distinct atrophic conditions, hindlimb immobilization and dexamethasone treatment. Leucine supplementation was able to minimize the reduction in rat soleus mass driven by immobilization. On the other hand, leucine supplementation was unable to provide protection against soleus mass loss in dexamethasone treated rats. Interestingly, HMB supplementation was unable to provide protection against mass loss in all treatments. While solely fiber type I cross sectional area (CSA) was protected in immobilized soleus of leucine-supplemented rats, none of the fiber types were protected by leucine supplementation in rats under dexamethasone treatment. In addition and in line with muscle mass results, HMB treatment did not attenuate CSA decrease in all fiber types against either immobilization or dexamethasone treatment. While leucine supplementation was able to minimize increased expression of both Mafbx/Atrogin and MuRF1 in immobilized rats, leucine was only able to minimize Mafbx/Atrogin in dexamethasone treated rats. In contrast, HMB was unable to restrain the increase in those atrogenes in immobilized rats, but in dexamethasone treated rats, HMB minimized increased expression of Mafbx/Atrogin. The amount of ubiquitinated proteins, as expected, was increased in immobilized and dexamethasone treated rats and only leucine was able to block this increase in immobilized rats but not in dexamethasone treated rats. Leucine supplementation maintained soleus tetanic peak force in immobilized rats at normal level. On the other hand, HMB treatment failed to maintain tetanic peak force regardless of treatment. The present data suggested that the anti-atrophic effects of leucine are not mediated by its metabolite HMB.
authors.affiliation: Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
authors.forename: Igor L
authors.initials: IL
authors.lastname: Baptista
authors.forename: Willian J
authors.initials: WJ
authors.lastname: Silva
authors.forename: Guilherme G
authors.initials: GG
authors.lastname: Artioli
authors.forename: Joao Paulo L F
authors.initials: JP
authors.lastname: Guilherme
authors.forename: Marcelo L
authors.initials: ML
authors.lastname: Leal
authors.forename: Marcelo S
authors.initials: MS
authors.lastname: Aoki
authors.forename: Elen H
authors.initials: EH
authors.lastname: Miyabara
authors.forename: Anselmo S
authors.initials: AS
authors.lastname: Moriscot
mesh_terms: D000818:Animals; D019587:Dietary Supplements; D019417:Hindlimb Suspension / Q000009:adverse effects; D007930:Leucine / Q000008:administration & dosage*; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D055948:Sarcopenia / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D014631:Valerates / Q000008:administration & dosage*
chemical_list: D014631:Valerates; C004961:beta-hydroxyisovaleric acid; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D046988:Proteasome Endopeptidase Complex; D007930:Leucine